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 Several foods and nutrients have been linked to prostate cancer risk, but the effect 
of overall diet on prostate cancer outcomes is not well understood. Previous research has 
primarily examined a posteriori dietary patterns in relation to prostate cancer; studies that 
have used a priori dietary patterns and their relationship with prostate cancer have been 
inconclusive. Furthermore, racial differences in prostate cancer incidence and 
aggressiveness are not well understood. Data from the case-only North Carolina-
Louisiana Prostate Cancer Project (PCaP) was used to examine the association between 
overall dietary pattern, as measured by the Mediterranean Diet (MED) score and the 
Dietary Approaches to Stop Hypertension (DASH) score, and prostate cancer 
aggressiveness in African-American (AA) and European-American (EA) men. Dietary 
patterns were assessed using a modified NCI Diet History Questionnaire for a final 
sample of 1,899 participants. Higher MED scores were found to be inversely associated 
with high aggressive prostate cancer overall (OR: 92; 95% CI: 0.84-0.99; p trend: 0.03); 
and results were similar for AA men and EA men. DASH scores were not significantly 
associated with prostate cancer aggressiveness. These results suggest that following a 
Mediterranean diet may decrease the risk of developing high aggressive prostate cancer. 
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1. Statement of problem 
General 
 Prostate cancer is the most commonly diagnosed cancer in American men and is 
the second leading cause of cancer mortality. There were an estimated 233,000 new 
prostate cancer cases diagnosed in the United States (U.S.) in 2014, accounting for 27% 
of all male cancer diagnoses; in the same year, 29,480 estimated deaths were attributed to 
prostate cancer, or 10% of all cancer-related deaths in American men (Siegel, Ma et al. 
2014). Between the years 1975-1988, incident rates of prostate cancer showed small 
increases; a sharp increase in the number of prostate cancer diagnoses in the years 1988-
1992 reflects the introduction of the prostate-specific antigen (PSA) blood test for 
screening, with the number of new cases declining in subsequent years (Edwards, Noone, 
et al. 2014; Siegel, Ma et al. 2014).  
 Several risk factors for prostate cancer are known, including age, race/ethnicity, 
and family history. The majority of new cases are diagnosed between the ages of 65-74 
years (36.6%), and less than 11% of all diagnoses occur in men younger than 55 years of 
age. Incidence rates differ by race: African Americans (AA) are more likely than any 
other race or ethnicity to be diagnosed with prostate cancer (223.9 new cases per 
100,000). American Indian and Alaskan natives have the lowest prostate cancer incidence 
(71.5 and 79.3 new cases per 100,000, respectively), while whites (139.9 new cases per
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 100,000) and Hispanics (121.8 new cases per 100,000) fall between the two extremes 
(Howlander, Noone et al. 2014). Family history has been shown to increase the risk of 
developing prostate cancer, with Grönberg finding a positive correlation between the 
number of affected family members and the risk of disease (2003).  
 Although prostate cancer is the most common cancer in men, the high 5-year 
survival rate (98.9%) and slow growth of prostate cancers has led to recent changes in the 
U.S. Preventive Services Task Force screening recommendations. In May 2012, they 
released a report that recommended against PSA screening tests for adult males without 
symptoms, citing the asymptomatic nature of most cases, high false-positive rates for the 
PSA screening test, and the potentially harmful side effects of treatment options (Moyer 
2012). Other cancer-related organizations advocate for screening only among high-risk 
individuals (older, AA men, and/or those with a family history). An alternative to the 
PSA blood test is the digital rectal exam (DRE), or the tactile examination of the prostate 
by a physician. Both methods are widely accepted, and the decision to perform either test 
is at the discretion of the primary care physician and patient. If prostate cancer is 
detected, treatment plans may be as mild as no action to as invasive as radical 
prostatectomy (Bill-Axelson, Holmberg et al. 2005).  
 Survival rates for prostate cancer remain high, even when measured at 10 (96.9%) 
and 15 (94%) years. These rates best reflect local and regional stage diagnoses; distant 
stage prostate cancers only have a 28% 5-year survival rate. Mortality rates also vary by 
race: AA men are almost twice as likely as European American (EA) or Hispanic men to 
die of prostate cancer (Howlander, Noone et al. 2014). Often, prostate cancer does not 
cause death: other health complications result in death before the metastasis of the tumor. 
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Given that the majority of diagnosed prostate cancers are indolent and not likely to cause 
clinical symptoms or death, there has been a recent shift in the focus on studying risk 
factors for overall prostate cancer to investigating risk factors for aggressive prostate 
cancer.  
Regional Disparities 
 The data for this population-based study were collected from men residing in 
Louisiana and North Carolina; these states exhibit distinctive prostate cancer statistics 
and trends. Louisiana had an estimated 3,720 new prostate cancer cases diagnosed in 
2014; the age-adjusted prostate cancer incidence rate in the state between 2006 and 2010 
was 169.3 new cases per 100,000 men. In North Carolina, an estimated 7,580 new cases 
were diagnosed, though the 2006-2010 incidence rate was lower, with only 151.9 new 
cases per 100,000 men. Both state’s incidence rates are higher than the national average 
(146.6 per 100,000 men) over the same time period. In 2014, approximately 920 deaths in 
men living in North Carolina were attributed to prostate cancer, while less than half that 
number (n=400) of deaths in Louisiana men were caused by prostate cancer. However, 
the prostate cancer mortality rate in Louisiana is slightly higher than in North Carolina 
(26.6 versus 25.8 deaths per 100,000), after adjusting for age (Siegel, Ma et al. 2014).  
Racial Disparities   
Incidence and Mortality 
 AA men have the greatest prostate cancer risk of any racial or ethnic group in the 
United States (Gann 2002). Between 2005 and 2009, prostate cancer incidence rates for 
AA men (228.8 per 100,000) and EA men (140.3 per 100,000) indicate that AA men are 
1.63 times more likely to develop prostate cancer than EA men. This disparity is more 
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pronounced when comparing mortality rates: AA men are 2.44 times more likely to die 
from prostate cancer than EA men (DeSantis, Naishadham et al. 2013). Several reasons 
that may account for this discrepancy are discussed further here. 
Screening and PSA  
 AA men are less likely than EA men to be screened for prostate cancer. In a study 
by Jones et al., EA men were significantly more likely to have received a DRE prostate 
cancer screening (OR=2.08, 95% CI: 1.03-4.21) than AA men; PSA screening tests also 
occur more frequently in EA men than in AA men (Jones, Liu et al. 2008; Carpenter, 
Howard et al. 2009; Carpenter, Godley et al. 2010). In a biracial sample of North 
Carolina men diagnosed with prostate cancer, Conlisk et al. found that having a recent 
PSA screening test was significantly (p=0.01) and inversely correlated with stage at 
diagnosis for AA men, but not for EA men (p=0.20) (Conlisk, Lengerich et al. 1999). A 
family history of prostate cancer was positively associated with having a recent PSA test 
(OR=3.03, 95% CI: 1.13-8.10), but not a DRE, in AA men (Bloom, Stewart et al. 2006).  
Disease Diagnosis and Treatment 
 The stage and grade of prostate cancer at time of diagnosis differs between AA 
men and EA men. Race is an independent predictor of prostate cancer stage at diagnosis, 
with AA men consistently presenting more advanced stage cancer than EA men 
(Schwartz, Crossley-May et al. 2003; Ward, Jemal et al. 2004). AA men are almost twice 
as likely to present with late stage prostate cancer then EA men; the likelihood of early-
stage diagnosis remains lower for AA men than EA men across socioeconomic status, 
clinical factors, and pathologic factors (Bennett, Ferreira et al. 1998; Ward, Jemal et al. 
2004; Hoffman, Gilliland et al. 2001; Jones, Liu et al. 2008). Measures of disease grade 
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(i.e., Gleason grade) tend to be higher in AA men: multiple studies have found that a 
higher proportion of AA men than EA men (20% versus 12%) will present with high-
grade tumors (Fowler & Bigler 1999; Reddy, Shapiro et al. 2003; Gaines, Turner et al. 
2014).  
  Despite their higher rates of diagnosis for distant stage prostate cancer, AA men 
are less likely to receive aggressive treatment therapies, namely radical prostatectomy 
(Klabunde, Potosky et al. 1998; Underwood, De Monner et al. 2004; Harlan, Potosky et 
al. 2001; Shavers, Brown et al. 2004).  They are also more likely than their EA 
counterparts to remain untreated (Tewari, Horninger et al. 2005).  Across all treatment 
options, mortality rates for AA men remain higher than for EA men (Godley, Schneck, et 
al. 2003); when access to care is adjusted for, disparities in outcome are attenuated across 
treatment arms (Optenberg, Thompson et al. 1995).  
Genetics 
 Family history is a long established risk factor for prostate cancer; a portion of the 
hereditary nature of prostate cancer occurrence has been attributed to genetic variants and 
gene-environment interactions (Schaid 2004; Stephenson 2008; Alvarez-Cubero, Saiz 
2013). Genes that have been linked with increased prostate cancer risk include: ELAC2 
(HPC2), MSR1, and RNASEL (HPC1) for familial cases; AR, ATBF1, EPHB2 (ERK), and 
KLF6 for sporadic cases; and AR, BRCA1, BRCA2, CHEK2 (RAD53), CYP17, CYP1B1, 
CYP3A4, GSTM1, GSTP1, GSTT1, PON1, SRD5A2, and VDR with both familial and 
sporadic cases (Dong 2006). Most of these genes are associated with tumor suppression, 
cell regulation, or androgen reception (Barbieri, Tomlins 2014). Racial differences in the 
frequency of allele presentation have been found and may explain part of the prostate 
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cancer disparities between AA and EA men (Ziegler-Johnson, Spangler et al. 2008; 
Freedland, Isaacs 2005).  
Socioeconomic factors 
 Socioeconomic status (SES) has been found to explain some of the prostate 
cancer disparities between AA and EA men. In a study conducted by Du, et al., lower 
SES was associated with decreased survival in all prostate cancer cases (HR: 1.31; 95% 
CI: 1.25-1.36); when comparing mortality between AA and EA men, socioeconomic 
status was found to be a significant factor in the survival disparities between the two 
groups (Du, Fang et al. 2006). SES has been found to have a greater impact on prostate 
cancer outcomes in AA men than EA men, both in terms of stage at diagnosis and 
mortality (Conlisk, Lengerich et al. 1999; Steenland, Rodriguez et al. 2004). Education, a 
common proxy for SES, has been shown to have a significant effect on mortality rates in 
AA men: those who completed 12 or less years of education had a prostate cancer 
mortality rate double that of men completing 12 or more years of education (RR: 2.17; 
95% CI: 1.82-2.58) (Albano, Ward et al. 2007). AA men have historically lower levels of 
SES and educational attainment than EA men; this likely has contributed to disparities in 
prostate cancer (U.S. Census Bureau 2012). 
Diet 
 Several individual components of dietary intake have been associated with 
prostate cancer occurrence, and differing levels of intake by race may account for some 
of the disparities in disease incidence. Increased intakes of fat, particularly animal fats, 
have been shown to be associated with increased prostate cancer incidence and fatality, 
with intake differences accounting for approximately 10% of AA-EA incidence 
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disparities (Gann 2002; Pelser, Mondul et al. 2013; Whittemore, Kolonel et al. 1995). 
Intake of dairy and dairy products above recommended levels has also been shown to 
modestly increase the risk of prostate cancer (Rodriguez, McCullough et al. 2003). 
Conversely, high intakes of soy, fiber, fruits and vegetables, and vitamins D & E, 
selenium, and lycopene (tomatoes) have been inversely associated with prostate cancer 
(Hardin, Cheng et al. 2011; Cheung, Wadhera et al. 2008; Hurst, Hooper et al. 2012). 
However, supplemental vitamin intake does not appear to be protective in reducing 
prostate cancer risk, and there is some suggestion that certain supplements (e.g., vitamin 
E) may be harmful under certain conditions, as seen in the Selenium and Vitamin E 
Cancer Prevention Trial (SELECT) (400 IU/day vitamin E intervention: HR: 1.13; 95% 
CI: 0.95-1.35; P = 0.06) (Lippman, Klein et al. 2009). Variations in intakes between AA 
and EA men, due to cultural eating habits, food availability, or gene-diet interaction may 
explain racial differences in prostate cancer (Reedy, Shapiro et al. 2003; Discacciati, 
Wolk 2014), and it is likely the combination of dietary factors, rather than single foods or 
nutrients alone, that will have the largest impact. 
2. Proposal and Specific Aims 
 The purpose of this case-only study was to examine the association between 
overall dietary pattern and prostate cancer aggressiveness, particularly in relation to racial 
disparities in prostate cancer between AA and EA men. Two dietary indexes, the 
Mediterranean Diet Score (MED), and the Dietary Approaches to Stop Hypertension 
(DASH), evaluate diet quality based on intakes of specific foods and food groups; the 
association between overall diet quality and prostate cancer aggressiveness, as 
determined by PSA count, stage and Gleason sum, in the large, case-only North Carolina-
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Louisiana Prostate Cancer Project (PCaP) was evaluated using these two dietary 
measures. My specific aim was to examine the relationship between diet quality and 
prostate cancer aggressiveness among AA and EA men using two different dietary 
indexes: 1) the MED diet score, as a measure of conformity to a Mediterranean diet; and 
the 2) DASH diet score as a measure of conformity to the Dietary Approaches to Stop 
Hypertension (DASH) diet.  
3. Significance of Research 
Prostate cancer is the most commonly diagnosed malignancy and the second most 
common cause of cancer mortality in American men (Siegel, Ma et al. 2014). Age, race, 
and family history are established risk factors for increased risk of prostate cancer; diet 
has been proposed as possible risk factor, yet evidence of the influence of overall dietary 
patterns remains inconclusive. To date, five studies have examined overall diet according 
to the MED or alternate MED (aMED) in relation to prostate cancer (Ax, Garmo et al. 
2014; Bosire, Stampfer et al. 2013; Kenfield, DuPre et al. 2014; Möller, Galeone et al. 
2013; Muller, Severi et al. 2009). None have used DASH to evaluate prostate cancer 
outcomes. The remaining body of evidence for total diet and prostate cancer is based on 
study-specific dietary patterns (Ambrosini, Fritschi et al. 2008; Askari, Parizi et al. 2014; 
De Stefani, Ronco et al. 2010; Jackson, Walker et al. 2009; Jackson, Tulloch-Reid et al. 
2013; Tseng, Breslow et al. 2004; Walker, Aronson et al. 2005; Wu, Hu et al. 2006). 
While there is a large body of literature on the association between individual dietary 
factors and prostate cancer, much of this evidence is contradictory and does not account 
for effects of other foods consumed. The lack of consistent measures of both individual 
diet components and overall dietary patterns hinders comparability across studies, and 
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impedes the formulation of dietary recommendations for prostate cancer prevention and 
treatment.  
This study utilized widely-accepted, standardized dietary indexes to evaluate overall diet; 
therefore, results are easy to interpret in the context of overall diet recommendations. 
Results from this study may support the adoption of the dietary pattern recommendations 




BACKGROUND & LITERATURE REVIEW 
1. Primary Hypothesis - Dietary Pattern and Prostate Cancer 
Dietary Patterns 
 A dietary pattern is defined as “the quantities, proportions, variety or combination 
of different foods, drinks, and nutrients in diets, and the frequency with which they are 
habitually consumed” (Krebs-Smith 2014). Rather than examining individual food or 
nutrient consumption, dietary pattern analysis attempts to examine disease outcomes in 
terms of habitual intakes of all foods, beverages, and supplements. The benefit of looking 
at overall intake patterns, as opposed to individual nutrient or food intakes, is that 
patterns attempt to account for “the highly interrelated nature of dietary exposures…. It is 
often difficult to separate out the specific effect of nutrients or foods… in relation to 
disease risk” (Jacques, Tucker 2001). The reductionist approach, or emphasizing the role 
of single nutrients or foods, is useful for identifying individual foods that have substantial 
health effects; however, using dietary pattern as a measure of nutritional exposure allows 
for study of the health effects of food combinations, often culturally specific, on disease 
prevention and outcomes (Jacobs, Steffen 2003).  
 Past research on the effect of dietary patterns on prostate cancer has relied on 
reported food intakes of the study population to determine the dietary patterns of 
analysis; the heterogeneity of diet quality assessment makes comparison and consensus 
of results difficult (see Table 2.1). The earliest study to examine the relationship between
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 patterns of dietary intake and prostate cancer was a cohort study conducted by Tseng, et 
al. using data from the National Health and Nutrition Examination Survey 
Epidemiological Follow-up Study cohort. The pattern, characterized by high intakes of 
fruits, vegetables, fish, and shellfish; a “red meat-starch” pattern, characterized by high 
intakes of red meats, potatoes, salty snacks, cheese, sweets, and desserts; and a 
“Southern” pattern, characterized by high intakes of beans, rice, cornbread, grits, sweet 
potatoes, and okra; none of the diets were found to be significantly associated with an 
increased risk of prostate cancer (Tseng, Breslow, et al. 2004). However, there was a 
non-significant inverse association for both the “red meat-starch” (highest tertile vs. 
lowest tertile RR: 0.8; 95% CI: 0.4-1.4) and “Southern” (RR: 0.6; 95% CI: 0.4-1.1) seen 
within the American men sampled. The protective effect seen with the “red meat-starch” 
pattern, given the similarity of the “red meat-starch” dietary pattern to the “Western” diet, 
is counterintuitive. The “Western” diet, characterized by high intakes of fatty meats, 
dairy products, refined cereals, salt, refined sugars, and refined vegetable oils, has been 
shown to be associated with the high rates of chronic disease in developed nations 
(Cordain, Boyd Eaton et al. 2005). Others have examined the association between the 
Western diet and prostate cancer: the majority of these studies have found a significant, 
positive association between a Western pattern of consumption and prostate cancer 
(Ambrosini, Fritschi et al. 2008; Askari, Parizi et al. 2014; De Stafani, Ronco et al. 2010; 
Walker, Aronson et al. 2005; Wu, Hu et al. 2006).  
 Patterns characterized by high intakes of fruit and vegetables have been shown to 
offer protection against prostate cancer incidence and aggressive forms of prostate 
cancer, but these associations were not statistically significant (Ambrosini, Fritschi et al. 
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2008; Askari, Parizi et al. 2014; De Stafani, Ronco et al. 2010; Jackson, Tulloch-Reid et 
al. 2013; Jackson, Walker et al. 2009; Muller, Severi et al. 2009; Walker, Aronson et al. 
2005; Wu, Hu et al. 2006).  
 Few studies have used a priori dietary pattern indexes in prostate cancer research. 
The index most commonly used to assess diet in relation to prostate cancer is the MED, 
or the closely related aMED. A cohort study of Swedish men did not find a significant 
association between high conformity to MED and odds of prostate cancer (OR: 1.01; 
95% CI: 0.75-1.37); they did find a significant, inverse relationship between eating a low-
carbohydrate, high-protein diet and prostate cancer (OR: 0.77; 95% CI: 0.61-0.96) (Ax, 
Garmo et al. 2014). Bosire et al. found in a cohort of American men that a high aMED 
score did not translate into a decreased risk of advanced prostate cancer diagnosis (HR: 
1.00; 95% CI: 0.87-1.15); and there was no association with risk of death from prostate 
cancer (HR: 0.80: 95% CI: 0.59-1.10) (Bosire, Stampfer et al. 2013). Other studies using 
MED or aMED measures, including a cohort, a case-only cohort, and case-control, also 
found no significant association with prostate cancer outcomes (Kenfield, Du Pre et al. 
2014; Möller, Galeone et al. 2013; Muller, Severi, et al. 2009).  
 Only one study has used the HEI-2010 to assess diet quality when exploring 
prostate cancer cases: HEI-2010 score was not significantly associated with the stage of 
diagnosis (HR: 1.10; 95% CI: 0.96-1.26) or with mortality (HR: 0.96; 95% CI: 0.71-1.30) 
of prostate cancer though there was an inverse association with total prostate cancer risk 
for those with high adherence to the HEI-2010 dietary guidelines (HR: 0.92; 95% CI: 
0.86-0.98) (Bosire, Stampfer et al. 2013). To our knowledge, the DASH index has not 
been used in any prostate cancer study to date.  
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Dietary Indices  
Mediterranean Diet Score 
 The Mediterranean diet specifically refers to food patterns typically seen in 1960s 
throughout Greece, Crete, and southern Italy: diets of people residing in these areas 
during the time period were characterized by high intakes of plant-based foods (fruits 
vegetables, whole grains, nuts, seeds, beans, and potatoes); seasonally fresh  and locally 
grown foods; dessert and sweet consumption limited to a few times a week; olive oil as 
the primary source of fat; low-to-moderate daily consumption of dairy products, fish, and 
poultry; low consumption of red meat; and moderate wine consumption. (Willett, Sacks 
et al. 1995). In the now-famous Seven Countries Study, Ansel Keys found that people 
adhering to what is now known as the Mediterranean diet had greatly reduced rates of 
coronary heart disease (Keys 1980). Trichopoulou et al. began scoring diets on their 
adherence to traditional Mediterranean diets in their 1995 study “Diet and overall 
survival in elderly people.” Median values of intakes for eight component characteristics 
(vegetables, legumes, fruits and nuts, dairy products, cereals, meat and meat products, 
ethanol, and monounsaturated:saturated fat ratio) were calculated: those with intakes 
above the median for positive components (vegetables, legumes, fruits and nuts, cereals, 
ethanol, and monounsaturated:saturated fat ratio, were given a score of 1 for that 
component, and those below the median were given a score of 0; meat and meat products 
and dairy products were scored in reverse. High scores (highest possible = 8) were found 
to be associated with improved survival in the elderly (Trichopoulou, Kouris-Blazos et al. 
1995). More recent versions have included scores for fish and poultry, increasing the 
maximum score to 9, with other scoring variations being used while maintaining similar 
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food groups (Trichopoulou, Costacou wt al. 2003; Panagiotakos, Pitsavos et al. 2006; 
Rumawas, Dwyer et al. 2009). Further applications have linked high MED scores to 
decreased incidence of colorectal, breast, and prostate cancers (Trichopoulou, Lagiou et 
al. 2000).  
Dietary Approaches to Stop Hypertension Score 
 The Dietary Approaches to Stop Hypertension (DASH) originated in a clinical 
trial of the same name: the multicenter, randomized feeding trial was designed to test the 
combined effects of food on blood pressure and found that certain dietary patterns could 
help control hypertension (Appel, Moore, et al. 1997). The diet emphasizes fruit, 
vegetable, low-fat dairy, whole grains, poultry, fish, and nut consumption while 
minimizing red meat, sweets, sugar-sweetened beverages, total fat, saturated fat, and 
cholesterol intakes (Sacks, Svetkey et al. 2001). A systematic review of cohort studies 
using the DASH score as a measure of dietary quality found a significant risk reduction 
in cancer incidence and mortality (RR: 0.85; 95% CI: 0.82-0.88) (Schwingshackl, 
Hoffmann 2015).  
Mechanisms 
 There are several ways that diet may influence prostate cancer risk. There is 
evidence to suggest that consuming certain foods may increase inflammation within the 
body, while other foods decrease inflammation (Cui, Jin et al. 2012; Cavicchia, Steck et 
al. 2009; Giugliano, Ceriello et al. 2006). Chronic inflammation has been linked with 
certain types of cancer, including prostate cancer: inflammatory markers, specifically C-
reactive protein (CRP) are high in men with metastases, and elevated CRP is associated 
with poor prognosis in men diagnosed with prostate cancer (Lehrer, Diamond et al. 2006; 
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Trautner, Cooper, et al. 1980; Latif, McMillan et al. 2002). Dietary fat may produce DNA 
damage through fatty acid oxidation into lipid radicals, increasing circulating androgen 
concentrations, inhibiting healthy cell communication and transduction, and negatively 
impacting the immune system (Kolonel 2001). Food preparation methods, especially 
charring meat, may also introduce carcinogens into the body, elevating cancer risk (De 
Marzo, Nakai et al. 2007; John, Stern et al. 2011). Fruits and vegetables contain a number 
of anticarcinogenic substances (such as carotenoids, flavonoids, isoflavones, among 
others), which can decrease cell proliferation, regulate DNA methylation, and increase 
apoptosis of cancer cells (Steinmetz, Potter 1996). Fiber, which increases sex-hormone-
binding globulin and improves insulin sensitivity, may decrease prostate cancer risk by 
reducing androgen levels in the blood and controlling antiapoptotic effects of circulating 
insulin (Tabung, Steck et al. 2012; Chan, Stampfer et al. 1998). Alcohol consumption, 
regardless of type, increases serum estrogen while decreasing androgens; it also weakens 
cell defenses against carcinogens (Dennis, Hayes 2001).   
Potential Confounders 
Age 
 Age is a known risk factor of prostate cancer: prostate cancer incidence is 
positively correlated with increasing age, peaking in the 65-74 age group (Howlander, 
Noone et al. 2014). In men under the age of 60, prostate cancer prevalence is much lower 
than other cancer types (Jemal, Siegel et al. 2009). Screening frequency decreases as age 
increases, and prostate cancer prognoses worsen with age (Zeliadt, Penson et al. 2003; 





 Another known risk factor for prostate cancer is family history. A diagnosis of a 
first-degree relation (father or brother) with prostate cancer approximately doubles a 
man’s prostate cancer risk; risk increases with the number of affected relatives (Crawford 
2003; Grönberg 2003). Genetics and common environment both play a role, though 
heritable genetic variations are estimated to contribute to 43% of cases diagnosed in the 
aged 55 and younger; genetics confer less risk as age of diagnosis increases (Carter, 
Beaty et la. 1992). Men with a familial history also tend to be diagnosed before the age of 
60, due in part to a greater propensity to receive prostate cancer screening (Bratt, Garmo 
et al., 2010; Crawford 2003).  
Screening 
 Previously, prostate cancer screening was recommended for all men beginning at 
age 50; with the release of the U.S. Preventive Task Force report on prostate cancer 
screening recommendations, only men with known risk factors or who are exhibiting 
symptoms are recommended to be tested. Current screening methods include the PSA test 
and the DRE: the PSA tests measures the level of PSA in blood serum (higher levels are 
associated with prostate cancer), while the DRE requires a physician to digitally feel the 
prostate for lumps, tenderness, hard areas, or general enlargement (Barrett 2002). AA 
men are less likely than EA men to be screened for prostate cancer, and screening is less 
likely to improve stage at diagnosis for AA men than EA men (Jones, Liu et al. 2008; 
Carpenter, Howard et al. 2009; Carpenter, Godley et al. 2010; Conlisk, Lengerich et al. 
1999). The high rates of survival associated with early stage prostate cancer have been 
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partially attributed to proactive screening programs in the last 20 years (Howlander, 
Noone 2014). 
Stage and Grade at Diagnosis 
 Prostate cancer progression is measured in four intervals according to the 
American Joint Committee on Cancer (AJCC) Tumor, Nodes, Metastases (TNM) system. 
In first stage prostate cancer, T1, the physician is unable to feel or see the tumor; often 
cancer in this stage is found incidentally or as a result of increased PSA levels. 
Progression to the next stage, T2, is characterized by tumor(s) that are able to be felt 
(with a DRE) or seen by ultrasound. T2 prostate cancer is still confined to the prostate. 
When the cancer has grown outside of the prostate, particularly the seminal vesicles, T3 
cancer is diagnosed; further spreading of the cancer cells from the prostate to the rectum 
and bladder tissues or bone marrow is classified as T4, or late stage prostate cancer 
(American Cancer Society 2015).  
 The Gleason system grades cancer tissues by appearance (as viewed under a 
microscope) and is the most common grading system for prostate cancers. Possible 
Gleason scores range from 2 (indicating well-differentiated cells in both primary and 
secondary patterns) to 10 (indicating poorly-differentiated cells in both primary and 
secondary patterns). Both cancer stage and grade are associated with prostate cancer 
outcomes, with later stage and higher grade cancers displaying higher mortality rates and 
shorter survival times (Drake, Keane et al. 2006; Gandaglia, Karakiewicz et al. 2014).  
Comorbidities 
 Comorbid conditions that are often found with prostate cancer include 
cardiovascular disease, hypertension, and diabetes; the Charlson Index uses a weighted 
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impact score to estimate the impact of these conditions on mortality (Charlson, Pompei et 
al. 1987). A greater Charlson score in prostate cancer cases increases the risk of non-
prostate cancer mortality, and this effect is greater in EA men than AA men (Chamie, 
Daskivich et al 2011; Putt, Long et al. 2009). In prostate cancer cases where comorbidity 
is high, non-aggressive treatments are recommended because of the greater risk of death 
from other causes (Daskivich, Chamie et al. 2011).  
Socioeconomic Status 
 Lower socioeconomic status has been shown to be associated with higher cancer 
risk and mortality rates, yet for prostate cancer, higher SES is associated with increased 
risk of prostate cancer diagnosis (Clegg, Reichman et al. 2009; Major, Norman Oliver et 
al. 2012). This phenomenon is often attributed to regular prostate cancer screenings in 
more affluent men, and is reflected in lower mortality rates for men of higher SES 
(Clegg, Reichman et al. 2009; Byers, Wolf et la. 2008). Education level, a common proxy 
for SES, is also associated with increased prostate cancer incidence, likely due to 
increased awareness of prostate cancer screening (Clegg, Reichman et al. 2009). 
Increased rates of insurance and access to health care, along with better quality health 
care likely account for better prostate cancer outcomes in those with greater SES (Du, 
Fang et al. 2006; Major, Norman Oliver et al. 2012).  
Body Mass Index 
 Higher body mass index (BMI) has been found to be associated with increased 
risk of aggressive forms of prostate cancer and prostate cancer mortality (Su, Arab et al. 
2011; Rodriguez et al. 2001; Hague, Van Den Eeden et al. 2014; Stacewicz-Sapuntzakis, 
Borthakur et al. 2008). Interestingly, one study found that high BMI increased the risk of 
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aggressive prostate cancer but offered protection for less-aggressive forms of the disease 
(Giovannucci, Liu et al. 2007). Excess weight may increase androgen production, leading 
to increased risk of prostate cancer by loss of tumor control (Stacewicz-Sapuntzakis, 
Borthakur et al. 2008).  
Physical Activity 
 Physical activity may lower risk of prostate cancer (Whittemore, Kolonel et al. 
1995; Giovannucci, Liu et al. 2007). A meta-analysis found consistent, protective effects 
of occupational, recreational, and total physical activity (Liu, Hu et al. 2011). The 
mechanisms of physical activity’s effect on prostate cancer are unclear, but proposed 
causes include enhanced immune systems, decreased hormone levels, and lower BMI 
(Lee, Sesso et al. 2001).  
Smoking 
 Smoking is a known causative agent of lung cancer, and has been shown to 
increase the risk of other cancers; however, evidence that smoking affects prostate cancer 
risk is inconclusive, as seen in Hickey et al.’s systematic review (2001). Several cohort 
and nested case-control studies have found positive but weak associations between 
smoking and prostate cancer incidence, but more have found no association at all 
(Hickey, Do et al. 2001; Giovannucci, Rimm et al. 1993). Smoking is known to affect 
male hormone levels, increase genetic mutation rates, and decrease immune function; 
upon this biological basis, smoking may be associated with prostate cancer, despite a lack 
of epidemiological evidence (Hickey, Du et al. 2001). The U.S. Surgeon General has 
concluded that smoking is a ‘probable’ contributor to prostate cancer mortality (US 




 There are inconsistent findings on the effect of alcohol on prostate cancer risk. 
One systematic review found moderate alcohol consumption (less than or equal to three 
drinks per day) is not associated with prostate cancer risk, but imbibing seven or more 
alcoholic drinks per day may increase prostate cancer risk (Dennis, Hayes 2001). A meta-
analysis of alcohol dose response found no association with prostate cancer, even at high 
doses (Rota, Scotti et al. 2012). Alcohol may increase cell permeability and inhibit cell 
repair mechanisms, leading to prostate cancer susceptibility (Dennis, Hayes 2001; Garro, 
Lieber 1990).  
Non Steroidal Anti-Inflammatory Drugs  
 Non steroidal anti-inflammatory drugs (NSAIDs) help decrease inflammation and 
reduce pain and fever. Common NSAID medications include aspirin, ibuprofen, and 
naproxen; regular use of these medications may confer a reduced risk of prostate cancer 
by reducing the damaging effects of chronic inflammation and inhibiting cyclooxygenase 
(COX) enzymes (Bosetti, Rosato et al. 2014; Wagenlehner et al. 2007). COX inhibitors 
have shown pro-apoptotic properties thought to regulate cell proliferation (Fleshner, 
Zlotta 2007). However, long-term use of some NSAIDs causes increased risk of 
cardiovascular problems and gastrointestinal bleeding, and severe side effects must be 
considered.  
Fats and Animal Meats 
 There is strong evidence that higher intakes of dietary fat and animal meats 
increase prostate cancer risk. Several ecologic studies have found a positive association 
between fat consumption and prostate cancer mortality and incidence (Stacewicz-
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Sapuntzakis, Borthakor et al. 2008; Rose, Boyar et al. 1986; Kolonel 2001). Cohort 
studies have consistently found strong, positive associations between saturated fat, animal 
fat, and meat consumption and prostate cancer (Stacewicz-Sapuntzakis, Borthakor et al. 
2008; Whittemore, Kolonel et al. 1991; Kolonel 2001; Hayes, Ziegler et al. 1999). In a 
study of Hawaii residents, high intake of saturated fats was estimated to account for 13% 
of prostate cancer cases (Hankin, Zhao et al. 1992); between 10-15% of the disparity in 
prostate cancer cases among AA, EA, and Asian American men has been attributed to 
differences in saturated fat intakes (Crawford 2003).  
Dairy Products, Calcium, and Vitamin D 
 There is probable evidence that diets high in calcium increase prostate cancer risk, 
though evidence that dairy products themselves increase risk is more limited (World 
Cancer Research Fund/American Institute for Cancer Research 2007). A meta-analysis 
conducted by Aune, et al. found that high intakes of total dairy products, milk, cheese, 
total calcium, and dairy calcium were associated with increased risk of prostate cancer 
(2015). Pettersson et al. found that whole milk consumption after prostate cancer 
diagnosis was positively associated with fatal outcomes (Pettersoson, Ksperzyk et al. 
2012; Song, Chavarro et al. 2013). However, calcium and dairy product intakes do not 
necessarily correlate, and results for one should not be interpreted for the other (Aune, 
Navarro Rosenblatt et al. 2015). 
 Vitamin D has been shown to exhibit anticancer effects on prostate cancer cells in 
laboratory settings (Schwartz 2009; Beer, Myrthue 2006). Studies on sunlight exposure 
and prostate cancer have shown generally positive benefits for increased UV exposure 
and prostate cancer outcomes (Schwartz 2013). It is hypothesized that “vitamin D 
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maintains the normal phenotype of prostatic cells and that vitamin D deficiency permit[s] 
the development of clinical prostate cancer from preclinical precursors,” though benefits 
of vitamin D may vary by calcium levels (Schwartz 2013).  
Fruits and Vegetables 
 High intakes of vegetables and fruits are the basis of most healthy diet 
recommendations, since the high nutrient density and low calorie density of these foods 
help maintain healthy weight and optimal body functions. Many antioxidants and 
flavonoids are found in fruits and vegetables, yet the literature does not provide 
convincing evidence that overall vegetable and fruit intakes affect prostate cancer 
outcomes in the United States (Stacewicz-Sapuntzakis, Borthakor et al. 2008; Wu, Hu et 
al. 2006). Cruciferous vegetables, including broccoli, cabbage, and Brussel sprouts, 
contain isothiocyanates which have demonstrated anticancer properties in laboratory and 
in vivo setting (Sing, Srivastava et al. 2005; Melchini, Traka et al 2013). Fiber is also a 
beneficial component of fruits and vegetables. Previously in PCaP, higher fiber intake 
was associated with reduced odds of high aggressive prostate cancer (Tabung, Steck et al. 
2012).  
Lycopene, Tomatoes, and Tomato-based products 
 While all vegetables are recommended for their numerous health benefits, 
tomatoes in particular, which contain lycopene, have been shown to offer protection 
against prostate cancer. Lycopene is a powerful antioxidant that may also help in DNA 
repair. Two meta-analyses found modest protective effects of lycopene (Etminan, 
Takkouche et al. 2004; Chen, Song et al. 2013). A review by the U.S. Food and Drug 
Administration (FDA) concluded that there is limited evidence supporting tomato and 
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lycopene consumption as a method of decreasing prostate cancer risk (Kavanaugh, 
Trumbo et al. 2007).  
Fish/omega-3 
Fish and fish oil (primarily omega-3 fatty acids) consumption do not have conclusive 
evidence of a positive or negative association with prostate cancer incidence, though a 
meta-analysis found a 63% percent reduction in cancer-specific mortality for men with 
the high levels of intake (Szymanski, Wheeler et al. 2010). Most studies, regardless of 
design, have found null or insignificant improvement in prostate cancer risk with 
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Q4 vs. Q1 
Vegetable:  
All cases: 1.13 
(0.72-1.78) p for 
trend: 0.46 
Aggressive cases: 
1.31 (0.77-1.24) p 
for trend: 0.31 
Non-Aggressive 
cases: 1.02 (0.57-
1.83) p for trend: 
0.77 
Western: 
All cases: 1.82 
(1.15-2.87) p for 
trend: 0.02 
Aggressive cases: 
2.11 (1.25-3.60) p 
for trend: <0.01 
Non-Aggressive 
cases: 1.41 (0.79-
2.53) p for trend: 
0.37 
Health Conscious: 
All cases: 1.06 
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1.53); p trend=0.28 
Abbreviations: MED, Mediterranean diet score; aMED, alternate Mediterranean diet score; HEI, Healthy Eating Index; 
AHEI, alternate Healthy Eating Index; BMI, body mass index (weight (kg)/ height (m
2
)); PA, physical activity; EI, energy 
intake (kcals); OR, odds ratio; RR, relative risk; 95% CI, 95% confidence interval; Q1, lowest quartile/quintile; Q4, highest 
quartile; Q5, highest quintile; T1, lowest tertile; T3, highest tertile; ref, reference level. 
a
 “Vegetable” pattern characterized by positive response loading to questions on vegetables listed; “Western” pattern 
characterized by positive response loading to questions on whole milk, white bread, eggs, refined sugar, fried potatoes, fried 
fish, red/processed meat including hamburgers, full-alcohol beer; “health conscious” pattern characterized by positive 
response loading to questions on steamed/grilled/tinned fish, chicken, rice, pasta, legumes, tofu, sprouts, nuts, yogurt, ricotta 
cheese, and red/white wine. 
b
 “Healthy” pattern characterized by high response loading of legumes, fish, dairy products, fruits, fruit juices, vegetables, 
boiled potatoes, whole cereal, and eggs; “Western” pattern characterized by high response loading of sweets, desserts, organ 
meats, snacks, tea, coffee, French fries, salt, carbonated drinks, and red and processed meats. 
c
 “Prudent” pattern characterized by high response loading of raw vegetables, citrus fruits, other fruits, and tea. 
“Traditional” pattern characterized by high response loading of lamb, dairy foods, cooked vegetables, and all tubers. 
“Substituter” pattern characterized by high response loading of fish and poultry and negative response loading for lamb. 
“Drinker” pattern characterized by high response loading on mate, beer, wine, and hard liquor. “Western” pattern 
characterized by high response loading on beef, processed meat, boiled eggs, fried eggs, and total grains. 
d
 “Healthy” pattern characterized by high response loading of vegetables, peas, beans, and fruits. “ Carbohydrate” pattern 
characterized by high response loading of white bread, refined cereals, poultry, rice/pasta, starchy roots and tubers. 
“Sugary foods and sweet baked products” characterized by high response loading of sugary foods, sweet baked goods, and 
non-diet drinks. “Organ meat and fast food” pattern characterized by high response loading of organ meat, fast food, and 
salty snacks. 
e
 “Healthy” pattern characterized by high response loading of vegetables, nuts, peas, and beans; “fast food” pattern 
characterized by high response loading of fast foods, alcoholic beverages, meal replacements, and dairy dessert; “meat” 
pattern characterized by high response loading of processed meat, eggs, poultry, and starchy fruits, roots, and tubers; 
“carbohydrate” pattern characterized by high response loading of rice/pasta, sugar-sweetened beverages, sweet baked 
goods, and poultry. 
f
 “Vegetable-Fruit” pattern characterized by positive response loading for vegetables, fruits, fish, and shellfish; “Red meat-
Starch” pattern characterized by positive response loading for red meats, potatoes, salty snacks, cheese, sweets, and 








 “Healthy Living” pattern characterized by high response loading of vegetables, fruits, whole grains, fish, and poultry; 
“traditional western” pattern characterized by high response loading of red meats, processed meats, milk, sweets, and hard 
liquor; “processed” pattern characterized by high response loading of processed meats, red meats, organ meats, refined 
grains, onions, tomatoes, vegetable oils, juices, bottled water, and soft drinks; “beverages” pattern was characterized by 
high response loading of tap water, soft drinks, fruit juices, potatoes, poultry and margarine, and inversely associated with 
beer, liquor, wine, and cream in coffee. 
h
 “Prudent pattern characterized by high response loading of fruits, vegetables, whole grains, fish, and poultry; “Western” 






This study utilized data from the North Carolina-Louisiana Prostate Cancer 
Project (PCaP), a population-based, case-only study designed to study racial differences 
in prostate cancer aggressiveness and survival. This research was designated as part of 
Project 3, nutritional modulation of prostate cancer aggressiveness, of the PCaP structure.  
2. Sample Size 
 A total of 2,258 men were recruited for participation in the PCaP sample 
population: of these, 1,130 identified as AA and 1,128 identify as EA. Approximately 
half (52%) of the participating men were North Carolina residents; the remaining men all 
resided in Louisiana.  
3. PCaP Methods 
Study Population 
As stated in paper “The North Carolina-Louisiana Prostate Cancer Project 
(PCaP): Methods and Design of a Multidisciplinary Population-Based Cohort Study of 
Racial Differences in Prostate Cancer Outcomes,” by Schroeder et al., “residents of the 
North Carolina and Louisiana study areas with a first diagnosis of histologically 
confirmed adenocarcinoma of the prostate [were] eligible to participate if they [were] 40-
79 years old at diagnosis, [could] complete the study interview in English, [did] not live 
in an institution (nursing home), [were] not cognitively impaired or in a severe debilitated
 
35 
 physical state, and [were] not under the influence of alcohol, severely medicated, or 
apparently psychotic at the time of the interview. 
“Eligible men also must self-identify as at least part African American/Black or 
Caucasian American/White in response to the open-ended interview question, ‘what is 
your race?’ Participants who indicated more than one group [were] asked if one best 
describes them; if not, multiple groups [were] recorded. This classification may be used 
as a proxy measure of race/ethnicity as a social construct or as a proxy measure of race as 
a biologic construct, as deemed appropriate for the individual PCaP Consortium projects. 
Participants [were] asked if they consider themselves to be Cajun, Creole, or 
Hispanic/Latino prior to the question about race, so that these ethnic groups [were] 
defined independent of African American or Caucasian American race/ethnicity. 
“North Carolina enrollment of patients diagnosed on or after July 1, 2004, began 
in September 2004. At present, the North Carolina study area consists of 42 counties 
Louisiana enrollment began in 13 parishes surrounding New Orleans in September 2004, 
but was discontinued because of Hurricane Katrina (August 29, 2005). This period of 
data collection (referred to as ‘Louisiana Phase I’) included study visits with 122 African 
American and 95 Caucasian American participants.” A second phase of Louisiana 
enrollment includes an expanded study area (including at least eight additional parishes in 
southern Louisiana. “Louisiana data and samples collected during Phase I will be 
analyzed separately from data and samples collected during Phase II and will be used 





Rapid Case Ascertainment 
“Eligible North Carolina patients [were] identified by the Rapid Case 
Ascertainment Core Facility, a collaborative effort of the UNC-Lineberger 
Comprehensive Cancer Center and the North Carolina Central Cancer Registry 
(NCCCR). North Carolina state law mandates regular reporting of all newly diagnosed 
cancers (excluding non-melanoma skin cancers), and the NCCCR is authorized to release 
contact and eligibility information to PCaP by the North Carolina Advisory Committee 
on Cancer Coordination and Control. In Louisiana, eligible patients [were] identified by 
the Louisiana Tumor Registry (LTR) in the School of Public Health at LSUHSC. LTR 
operations are mandated by Louisiana law, which directs all hospitals, pathology 
laboratories, health care facilities, and medical care providers to report cancer cases or 
provide LTR staff with access to this information. Case ascertainment field 
representatives abstract[ed] pathology reports, review[ed] information used to screen 
eligibility and ensure[d] that ascertainment in hospitals and local urology clinics [was] as 
complete and rapid as possible.\ These data [were] entered into a relational database that 
[was] regularly downloaded into the PCaP Subject Tracking Database (Schroeder, 
Bensen et al. 2006).”  
Randomized Recruitment 
“Caucasian Americans account[ed] for a greater proportion of North Carolina 
patients than African Americans; therefore, a randomized recruitment procedure [was] 
used to generate comparable ascertainment and enrollment rates by race and state over 
the entire enrollment period. This sampling method improve[d] efficiency without 
compromising estimation of main effects and risk difference modification (additive scale 
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interactions) by race, and appropriate analysis requires only that the sampling 
probabilities are included as stratum-specific offset terms in some analytic models. To 
apply randomized recruitment, each ascertained case [was] assigned a random number 
and recruited only if that number [was] less than or equal to its race specific sampling 
probability, which is 100% for African Americans and 44% for Caucasian Americans 
(Schroeder, Bensen et al. 2006).” 
Physician Notification 
“Recruitment [began] with a mailed request to the diagnosing physician for 
permission to contact their patient, as mandated by the North Carolina and Louisiana 
cancer registries. Written physician permission [was] not required; instead, physicians 
[were] given 3 weeks to notify PCaP if a patient should not be contacted for any reason, 
including ineligibility due to mental illness or impairment, nursing home residence, or 
severe physical debilitation. Passive physician permission, and access to patient 
information under a limited waiver of consent to identify and contact potential PCaP 
participants, was approved by the UNC and LSUHSC IRBs and DoD HSRRB 
(Schroeder, Bensen et al. 2006).” 
Enrollment 
“Patients with active or passive physician consent [were] sent an introductory 
letter and brochure describing PCaP. One week later an experienced enrollment specialist 
[called] to confirm eligibility, explain the study, answer questions, solicit participation, 
and schedule an in home visit. Demographic and pathology report data (without 
personally identifiable information) [were] retained for cases who could not be contacted 
or who decline[d] participation, so that characteristics of non-participants could be 
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compared with those of participants to assess potential selection bias. Reasons for 
declining participation [were] recorded when known. Enrollment specialists [were] 
required to make multiple attempts to contact each potential participant. If a valid phone 
number could not be identified, the patient’s urologist [was] asked to provide the patient 
with the PCaP introductory letter at his next appointment. Patients who could not be 
contacted within 90 days [were] sent a letter asking them to contact the study directly. If 
no contact [was] made within the next 30 days, the patient [was] classified as ‘unable to 
contact.’(Schroeder, Bensen et al. 2006) “ 
Study Visit 
“Participants [were] visited in their home (or other location of their choosing) by 
a trained Registered Nurse. Participants [were] asked to fast for 6 hr prior to the study 
visit, which [was] scheduled in the morning whenever possible, and to gather all 
medications and supplements used in the 2 weeks prior to the visit. Study nurses [began] 
each visit by explaining the study and obtaining HIPAA authorization and formal written 
informed consent to: (1) conduct the questionnaire interview, (2) make anthropometric 
measurements, (3) obtain samples of adipose tissue, blood, urine, and toenails, (4) allow 
temporary release of paraffin embedded prostate tissue blocks, and (5) allow retrieval and 
abstraction of medical records. Study consent forms [were] read aloud to illiterate 
participants in the presence of a witness not associated with PCaP. After consent forms 
[were] signed, the study nurse collect[ed] biologic samples, [made] anthropometric 
measurements and administer[ed] the questionnaire. Study visits [took] approximately 4 
hr to complete, including two 15-min breaks. Participants [were] partially compensated 
for their time with a payment of up to $75 for completing the entire PCaP study visit. 
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“All study visit protocols [were] documented in a manual of procedures. To 
ensure consistency, patient safety, and confidentiality, study nurses must be certified and 
periodically re-certified to conduct all aspects of the visit. Interview and biologic sample 
collection data [were] reviewed on an ongoing basis to identify variation among study 
nurses or between study sites that cannot be explained by acceptable or expected trends. 
In addition, project managers at each site call randomly selected study participants after 
study visits [were] completed to assess nurse performance and solicit feedback 
(Schroeder, Bensen et al. 2006).”  
Anthropometric Measures 
“Weight (to the nearest 0.1 kg), height, and waist and hip circumferences (in cm) 
[were] measured after biologic sample collection using standardized instruments. 
Participants [were] asked their usual weight and height at age 25 and their weight 1 year 
prior to the visit (Schroeder, Bensen et al. 2006).” 
Study Questionnaires 
“Study nurses administer[ed] a series of structured questionnaires that solicit[ed] 
information regarding: 
Background characteristics: self-described race and ethnicity, marital status, religion, 
education, income, tobacco use, physical activity. 
Occupation: current employment, occupation and industry, longest and second 
occupation and industry, military service, occupations associated with pesticide use. 
Family history: prostate cancer in first- and second-degree relatives. 
Health status: general health and comorbid conditions. 
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Health care: usual sources of care, health insurance, traditional health beliefs, perceived 
access, and quality of care. 
Prostate cancer diagnosis and screening history: PSA tests, digital rectal exams, urinary 
and sexual symptoms, previous prostate biopsies. 
Medication survey: all prescription and over-the-counter medications and supplements 
used in the prior 2 weeks (transcribed by study nurses). 
Non-steroidal anti-inflammatory drugs (NSAIDs): frequency and duration of use for 
prescription and over-the-counter NSAIDs taken during the past 5 years at least once a 
month for 1 week or longer, with product name show cards to aid recall. 
Vitamins and supplements (including herbal products). 
Diet History Questionnaire (DHQ): The DHQ was developed by the National Cancer 
Institute and modified by PCaP Project 3 investigators to include Southern foods. The 
DHQ asks about intake frequency and usual portion size for 124 food items, as well as 
food preparation methods. Participants are asked to recall their usual diet for the year 
prior to diagnosis. Questionnaire responses are linked to the updated DHQ Nutrient 
Database through the NCI-developed Diet*Calc software to estimate intake of fatty acid 
and antioxidant micronutrients, including omega-3 and omega-6 polyunsaturated fatty 
acids, carotenoids, and tocopherols (Schroeder, Bensen et al. 2006).” 
Medical Records Retrieval and Abstraction 
“Medical records [were] requested from the diagnosing physician of consenting 
participants. Trained staff use[d] a relational database designed specifically for PCaP to 
abstract information concerning comorbid conditions, family history of prostate cancer, 
urologic symptoms, indications for diagnostic examinations and biopsies, prostate cancer 
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screening examinations, and laboratory assays at or near diagnosis, imaging examinations 
used in staging, clinical stage and grade (as recorded), and initial treatment information. 
In addition, abstractors independently derive[d] clinical stage according to a standardized 
protocol. Pathologic stage, grade, and other prostatectomy data [were] recorded 
separately, when available. Approximately 10% of medical records [were] selected at 




 Cases were classified in three categories based on clinical grade (Gleason grade), 
clinical stage, and PSA at diagnosis. High aggressive cases were defined as having a 
Gleason sum ≥8 OR PSA>20 ng/ml OR Gleason sum=7 and stage T3-T4; low aggressive 
cases were defined as having a Gleason sum<7 AND stageT1-T2 AND PSA<10 ng/ml; 
all other cases were classified as intermediate aggressive. For the purposes of this study 
and all included analyses, cases were dichotomized into high aggressive (as defined 
above) and low-intermediate aggressive (all other cases). This dichotomization will allow 
for the calculation of the odds of high aggressive prostate cancer, and analyses to be 
conducted similarly to a case-control study where men with high aggressive prostate 
cancer will serve as “cases” and men with low or intermediate aggressive prostate cancer 






Main Exposures: Dietary Pattern Score 
Mediterranean Diet Score 
 The MED scores followed the scoring scheme outlined by Trichopoulou, et al. 
(2003). A total of nine dietary components were evaluated: grains and cereals, refined 
grains, fatty acids, vegetables, legumes, fruits and nuts, fish, and alcohol. The median 
intake value (in grams per day) for each component was calculated from the sample 
scores for the nine components reflect if intake was above or below the median. For 
grains and cereals, fatty acids (calculated as the ratio of monounsaturated fatty acids to 
saturated fatty acids in g/day), vegetables, legumes, fruits and nuts, and fish, intakes 
above the median were scored 1 and intakes below the median were scored 0. Refined 
grains and meat and poultry were scored 1 for intake values below the median, 0 for 
values above the median. An alcohol score of 1 was given to men consuming 10-50 g 
alcohol/day; all other alcohol intake ranges were scored 0 (see Table 3.1). 
Median cutoff values were calculated from the responses given in cups/ounces per day. 
For mixed dishes, the percentage of each relevant component were estimated using 
common recipes; that percentage was applied to the cup/oz. value, and summed into the 
total component value. All values were adjusted to reflect intake in grams/day. 
Dietary Approaches to Stop Hypertension Score 
 DASH scores followed the scoring scheme outlined by Fung et al. (2008): eight 
components (whole grains, low fat dairy, vegetables, legumes and nuts, fruit and fruit 
juices, red and processed meats, sodium, and sweetened beverages) were scored on a 1-5 
scale. For whole grains, low fat dairy, vegetables, legumes and nuts, and fruit and fruit 
juices, the highest intake quintiles received a score of 5, with the lowest quintile receiving 
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a score of 1; for red and processed meats, sodium, and sugar sweetened beverages, the 
scoring scheme is inverted (lowest quintiles receive scores of 5). Scores may range from 
8-40, with 40 reflecting the healthiest patterns of consumption (see Table 3.1).  
 Values may be evaluated as reported, since evaluation is based on quintiles and/or 
tertiles. For mixed dishes, the percentage of each relevant component will be estimated 
using common recipes; that percentage will be used to calculate the serving amount and 
summed into the total component value. Responses were standardized across frequency 
to achieve a common time denominator. 
Potential Confounders and/or Effect modifiers 
Age: Age was included as a continuous variable. 
Race: Race was dichotomized into AA and EA men. 
Study Site: Site was designated as either North Carolina (University of North Carolina) 
or Louisiana (post-Hurricane Katrina, Louisiana State University).  
Family History: Family history was dichotomized into “yes” or “no”: those coded as 
“yes” positively indicated prior prostate cancer diagnoses in their family; all others were 
coded as “no.” 
Education: Education was defined on four levels: less than high school diploma, earned 
high school diploma, some college/VoTec, and college graduate (including post-graduate 
studies).  
Screening History: Screening history was defined on four levels: PSA test only, DRE 
only, PSA and DRE tests, and neither PSA nor DRE test.  












Smoking Status: Smoking status was defined as current smoker, past smoker, and never 
smoker.  
NSAID Use: NSAID use was dichotomized into “yes” for those reporting regular use and 
“no” for all others.  
Physical Activity: MET hours per week were calculated from reported physical activity 
levels and frequencies. 
Comorbidity: Comorbidity was assessed using Charlson’s Comorbidity Index; scores 
were categorized into 0, 1-2, and 3 or greater.  
5. Analyses 
Missing Data 
 Any participants missing outcome, covariate, or exposure data were not included 
in the final analyses.  
Statistical Methods 
 All procedures were performed using SAS, version 9.4 statistical software with 
the intention of determining: 
1. Diet scores, evaluated as numeric variables and as categorical variables. MED 
scores were categorized as low (0-3), moderate (4-5) and high (6-9) conformity. 
DASH scores were evaluated using two categorizations, tertiles and quintiles, 
where cutpoints were determined based on the distribution among low-
intermediate aggressive cases. 
2. Univariate distributions of exposures, outcomes, and potential covariates.  
3. Logistic regression (2-level outcome) simple model for each dietary score, 
including dietary score, age, total energy intake, and race. 
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4. Multivariate logistic regression models further adjusting for study site, family 
history, BMI, education level, screening history, smoking status, physical activity, 
NSAID use, and comorbidities. Decisions to include these covariates in the model 
were based on previous literature and the “ten percent rule.” Variables were added 
separately one at a time to the crude model, and percent change in the beta-
coefficient for the exposure was calculated. If the percent change was equal to or 
greater than 10%, then variables were retained in the final model.  
5. P-values for linear test for trend, with the exposures evaluated as both numeric 
variables and categorical variables. Categorical linear trend tests were conducted 
using an ordered dummy variable in lieu of category. 
6. Possible effect modification by race, age, smoking status, and BMI were 
identified by inclusion of an interaction term of dietary score*covariate in the 
model; interaction terms significant at the 0.10 level, and that changed the OR by 
more than 10%, were included in the final model. Stratification by effect 
modifiers was performed to estimate effects within strata of age, smoking and 
BMI.  
7. Pearson correlation between the MED and DASH scores was calculated. 
8. Average intakes for total energy, fat, saturated fat, carbohydrates, protein, 
polyunsaturated fatty acids, monounsaturated fatty acids, alcohol, lycopene, 
calcium, vitamin A, vitamin C, vitamin E, vitamin D, and fiber were calculated 






Logit (P(prostate cancer aggressiveness)) = β0 + β1(dietary index score) + β2(age) + 
β3(race) + β4(total energy intake) + β5(education) + β6(smoking) + β7(BMI) + β8(PA 



















Grains/Cereals ≥median g/day 0-1   




Dairy ≤median g/day 0-1   









0-1   




   Legumes ≥median g/day 0-1   






Fruit     
   Total fruit   






   Fruit and 
nuts 
≥median g/day 0-1   
Protein     
   Fish ≥median g/day 0-1   
   Meat & 
Poultry 
≤median g/day 0-1   
   Red and 
processed 









Alcohol 10-50 g/day (men) 0-1   







 Taken from “Adherence to a Mediterranean diet and survival in a Greek 
population” by Trichopoulou A., T. Costacou, et al., 2003. 
b
 Taken from “Adherence to a DASH-style diet and risk of coronary heart disease 





Tables 4.1 - 4.2: Descriptive Statistics 
 The final sample size included 1,899 men, with 1,567 low-intermediate 
aggressive cases of prostate cancer and 332 high aggressive cases of prostate cancer. 
Within the sample, 908 of the men identified as AA (47.8%) and 991 identified as EA 
(52.2%). MED scores ranged from 0 to 9 with a mean and SD of 4.19 ± 1.65. DASH 
scores ranged from 11to 36 with a mean and SD of 22.01 ± 4.37; both MED and DASH 
scores were normally distributed. 
Aggressiveness Comparisons (Table 4.1) 
 Participants diagnosed with high aggressive prostate cancer were significantly 
older, had higher body mass index, consumed more calories per day, identified as AA, 
were more likely to have less than a high school education, were more likely to be current 
or former smokers, and were less likely to have been screened for prostate cancer 
previously than low-intermediate cases.  
Racial Differences (Table 4.2) 
 AA men included in this study were younger, less active, consumed more calories 
per day, were less educated, more likely to be a current smoker, less likely to use 
NSAIDs regularly or to have been previously screened for prostate cancer, and had fewer 
comorbidities than their EA counterparts.
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Tables 4.3 - 4.4: Confounding   
 Previous research has indicated that BMI, physical activity, education level, 
smoking status, NSAIDs use, family history, screening history, and comorbidities may 
confound the association between dietary measures and prostate cancer (Ax, Garmo, et al 
2014; Bosire, Stampfer, et al. 2012; Tseung, Breslow, et al. 2004). Therefore, all these 
factors were justified for inclusion in the fully adjusted logistic regression models. To 
determine which of these known confounders presented as such in this dataset, the “ten 
percent rule” was used to assess each covariate: screening history and smoking history 
were found to highly impact the numeric dietary scores, while BMI, education  level, 
smoking history, family history, and screening history showed substantial changes to 
dietary score estimates when evaluated categorically. 
Tables 4.5 - 4.8: Final Models 
Numeric dietary pattern scores (Tables 4.5-4.6) 
 For all men, higher MED and DASH scores were significantly inversely 
associated with the odds of aggressive prostate cancer: for every one point increase in 
MED score, odds of aggressive prostate cancer diagnosis decreased by 12%  (95% CI: 
0.82 -0.96), while a point increase in DASH score decreased aggressive diagnosis odds 
by 4%  (95% CI: 0.93, 0.99). After adjusting for all confounders, the statistically 
significant inverse associate between MED score and odds of aggressive prostate cancer 
remained, while the association seen for the DASH score was attenuated.  
 Interaction p-values for race and diet scores were not statistically significant (p 
interaction= 0.11 and 0.15 for numeric MED and DASH scores, respectively). However, 
because one of our a priori aims was to examine associations by race, we stratified 
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primary analyses by race and present those results in Table 4.6. In EA men, a decrease in 
aggressive prostate cancer diagnosis of 12% and 5% were observed with increasing MED 
and DASH scores, respectively; the inverse association remained within the sample but 
there is not enough evidence to detect this relationship to the population. For AA men, 
higher MED scores were associated with lower odds of aggressive prostate cancer 
diagnosis (OR: 0.89; 95% CI: 0.80-0.99), though the effect was not significant when 
adjusted for multiple confounders. No significant association between DASH scores and 
aggressiveness was observed in AA men. 
Categorical dietary pattern scores (Table 4.7-4.8) 
 As shown in Table 4.7, men with the highest MED scores (6-9) had a 34% 
decreased odds of an aggressive prostate cancer diagnosis compared to men with the 
lowest MED scores (0-3) (p trend: 0.09). The odds of aggressive prostate cancer 
decreased by 35% for men in the highest tertile of DASH scores compared to men in the 
lowest tertile (p trend: 0.02); this association was attenuated and no longer statistically 
significant in the adjusted model (OR: 0.76; 95% CI: 0.55-1.06; p trend = 0.23). When 
comparing DASH quintiles, men in the second highest quintile were significantly less 
likely to be diagnosed with aggressive prostate cancer than men in the lowest quintile 
(OR: 0.63; 95% CI: 0.43-0.92). When AA men and EA men were evaluated separately, 
AA men with the highest MED scores were less likely to have aggressive prostate cancer 
than AA men in with the lowest MED scores (OR: 0.56; 95% CI: 0.32-0.97) (Table 4.8).  
Tables 4.9 - Table 4.11: Effect Modification  
 The interaction term with BMI was significant in the numeric DASH models (p 
interaction term = 0.09), but not for any categorized DASH models or MED models. 
 
51 
Although the interaction terms were not significant, higher MED and DASH scores 
appeared to have the most beneficial effect on men classified as ‘overweight (BMI 25 or 
greater but less than 30). Age (‘less than 65 years’ and ‘65 years or older’) and smoking 
status had significant interaction terms in all MED score models and in numeric DASH 
models. Increased conformity to both MED and DASH dietary patterns showed larger 
inverse associations for men aged 65 and older than for men younger than 65 on 
aggressive prostate cancer diagnosis. For all models, never and former smokers were 
observed to have lower odds of aggressive prostate cancer than current smokers. 
Tables 4.12 - Table 4.15: Sensitivity Analyses Using Categorized Age Models  
 Analyses re-run with age categorized into ‘less than 65 years’ and ’65 years or 
older’ showed no substantial deviation from results found with the continuous age 
variable included in the model.  
Table 4.16: Spearman Correlation between MED and DASH scores  
 Moderate, positive linear associations were found between numeric MED and 
DASH scores, MED categories and DASH quintiles, and MED categories and DASH 
tertiles for all men, AA men, and EA men (correlation coefficients were 0.53 for numeric 
variables and 0.46 for categorical variables, all p values <0.0001). 
Table 4.17: Means and Standard Deviations of Select Nutrients Across Total Sample 
and Dietary Score Categories  
 Table 4.17 shows the average intakes of select nutrients across the total sample 
and dietary score categories. For all dietary score categories, those with the highest scores 
also has the highest intakes of energy, fat, carbohydrates, protein, polyunsaturated fatty 
acids, monounsaturated fatty acids, lycopene, vitamin A, vitamin C, vitamin E, vitamin 
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D, and fiber; the exceptions were calcium and saturated fat, where those with moderate 
adherence to the MED diet had the highest calcium consumption when compared to low/ 
high MED adherence, and alcohol, where there was no universal trend of consumption 
for any of the dietary categories. For all nutrients except alcohol, participants in the 
highest dietary score category had an average intake above the sample average. 
Tables 4.18-4.19: Comparison of Research Participants Included in Analyses to 
Those Excluded Due to Missing Data  
 Men with missing PSA screening history/Gleason scores, implausible caloric 
intakes (<500 kcal/day or >6000 kcal/day), and/or missing covariate information (n=359) 
were excluded from final analyses. Excluded men were compared to included men to 
determine if data was missing at random or in association with the outcome; those 
missing other covariates were more likely to be diagnosed with aggressive prostate 
cancer (p value = 0.04), indicating the missing data may be associated with the outcome. 
Men excluded from analyses consumed more calories each day and were less physically 
active; they were also more likely to identify as AA, reside in Louisiana, have less 
education, be a current smoker, and have never been screened for prostate cancer. 
 All adjusted models were rerun, including all men with aggressive data (both 
included in primary analysis and those excluded for missing data) for comparison with 
association measures of included subjects; further sensitivity analysis was conducted by 
artificially placing all high aggressive cases with missing variables into the highest 
categories of dietary scores and artificially placing all low-moderate aggressive cases 
with missing variables into the lowest categories of dietary scores (Table 4.19). These 
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sensitivity analyses revealed similar results to the main analyses, suggesting that the 






Table 4.1: Dietary and demographic characteristics of PCaP participants by high and low-intermediate aggressiveness (after 
excluding participants with missing covariates) 
Characteristic High Aggressive (n=332) Low-Intermediate Aggressive 
(n=1567) 
p-value* 
 Mean SD Mean SD  
MED Score 4.0 1.6 4.2 1.7 0.06 
DASH Score 21.6 4.2 22.1 4.4 0.06 
Age 64.7 7.8 62.8 7.9 <0.0001 
Body Mass Index 30.2 6.0 29.1 5.0 0.002 
MET hours per week 22.3 22.9 24.2 23.6 0.18 
Total energy intake (kcal) 2594.3 1121.3 2458.6 1022.6 0.04 
 n % n %  
Race     0.005 
     AA 182 54.8 726 46.3  
     EA 150 45.2 841 53.7  
Site     0.35 
     LA 179 53.9 801 51.1  
     NC 153 46.1 766 48.9  
Education     <0.0001 
     Less than High     School 96 28.9 282 18.0  
     High School Graduate/Vo-Tech 
school 
91 27.4 483 30.8  
     Some college/College Graduate 111 33.4 565 36.1  
     Graduate/Professional Training or 
Degree 
34 10.2 237 15.1  
Smoking Status     0.003 
     Never 93 28.0 555 35.4  
     Former 173 52.1 798 50.9  
     Current 66 19.9 214 13.7  






     No  127 38.3 617 39.4  
     Yes 205 61.8 950 60.6  
Family history in first degree relative     0.45 
     No 260 78.3 1144 73.0  
     Yes 72 21.7 423 27.0  
Screening history     <0.0001 
     None 73 22.0 164 10.5  
     DRE only 60 18.1 230 14.7  
     PSA only 17 5.1 60 3.8  
     DRE & PSA 182 54.8 1113 71.0  
Charlson’s Comorbidity Index     0.33 
     0 155 46.7 799 51.0  
     1-3 152 45.8 669 42.7  
     4+ 25 7.5 99 6.3  
*
P-value for differences between cases and controls determined by t-test for numeric variables and chi-square test for categorical 
variables. 
a 
Prostate cancer aggressiveness is defined as the severity of the cancer at diagnosis based on combinations of the Gleason score, 
morphologic stage, and PSA as follows: high aggressive, Gleason sum ≥ 8 OR PSA > 20 ng/mL OR Gleason sum ≥ 7 and stage T3-






Table 4.2: Dietary and demographic characteristics of PCaP participants by race (after excluding those with missing 
covariates)
 
Characteristic African Americans 
(n = 908 ) 
European Americans 













MED score 4.7 1.9 4.1 1.9 <0.0001 
DASH score 23.8 4.1 24.2 4.2 0.01 
Age (years) 61.9 7.8 64.2 7.9 <0.0001 
Energy Intake (kcal/d) 2654.1 1165.9 2324.9 884.5 <0.0001 
Body Mass Index (kg/m
2
) 29.3 5.6 29.3 4.9 0.97 
MET hrs/wk 21.3 22.7 26.3 23.9 <0.0001 
 n % n %  
Prostate cancer classification
a
     0.005 
   High Aggressive 182 20.0 150 15.1  
   Low-Intermediate Aggressive 726 80.0 841 84.9  
Site     0.58 
   Louisiana 475 52.3 505 51.0  
   North Carolina 433 47.7 486 49.0  
Education level     <0.0001 
   < 8
th
 grade/some high school 283 31.2 95 9.6  
   High school grad/vo-tech 302 33.3 272 27.4  
   Some college/college grad 265 29.2 411 41.5  
   Graduate school/prof. degree 58 6.3 213 21.5  
Smoking status     <0.0001 
   Never 282 31.1 366 36.9  
   Former 432 47.6 539 54.4  
   Current 194 21.3 86 8.7  
Use of NSAIDs     <0.0001 






   Yes 501 55.2 654 66.0  
Family history (first degree relative 
affected) 
    0.11 
   No  656 72.2 748 75.5  
   Yes 252 28.8 243 24.5  
Screening history (PSA or DRE)     <0.0001 
   None 171 18.8 66 6.7  
   DRE 187 20.6 103 10.4  
   PSA 34 3.7 43 4.3  
   DRE & PSA 516 56.8 779 78.6  
Charlson’s Comorbidity Index     0.03 
   0 427 47.0 527 53.2  
   1-3 418 46.0 403 40.7  
   4+ 63 7.0 61 6.1  
*
 P-value for differences between AAs and EAs determined by t-test for numeric variables and chi-square test for categorical 
variables. 
a 
Prostate cancer aggressiveness is defined as the severity of the cancer at diagnosis based on combinations of the Gleason score, 
morphologic stage, and PSA as follows: high aggressive, Gleason sum ≥ 8 OR PSA > 20 ng/mL OR Gleason sum ≥ 7 and stage T3-
T4; low aggressive, Gleason sum < 7 and stage T1-T2 and PSA < 10 ng/mL; intermediate aggressiveness, all other cases. 
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Table 4.3: Assessment of confounding by 10% rules for covariates – numeric diet 
scores 
 MED Score 
Beta 
Coefficient 





1 -0.1244  -0.0429  
BMI -0.1172 -5.79 -0.0412 -3.96 
METs/week -0.1225 -1.53 -0.0417 -2.80 
Site -0.1256 0.96 -0.0429 0 
Education -0.1171 -5.87 -0.0390 -9.09 
Smoking History -0.1163 -6.51 -0.0371 -13.52 





-0.1220 -1.93 -0.0435 1.40 




-0.1240 -0.32 -0.0430 0.23 
1






Table 4.4: Assessment of confounding by 10% rules for covariates – categorical diet scores 




Moderate 0.0268  Q2 0.1968  T2 -0.0267  
High -0.2963  Q3 -0.0376  T3 -0.1997  
   Q4 -0.2291     
   Q5 -0.1654     
BMI 
Moderate 0.0226 -15.67 Q2 0.2123 7.88 T2 -0.0342 28.09 
High -0.2749 -7.22 Q3 -0.0540 43.62 T3 -0.1869 -6.41 
   Q4 -0.2297 0.26    
   Q5 -0.1477 -10.70    
Physical activity in METs/week 
Moderate 0.0265 -1.12 Q2 0.1946 -1.12 T2 -0.0275 3.00 
High -0.2930 -1.11 Q3 -0.0386 2.66 T3 -0.1932 -3.25 
   Q4 -0.2254 -1.62    
   Q5 -0.1569 -5.14    
Site 
Moderate 0.0267 -0.37 Q2 0.1984 0.81 T2 -0.0265 -0.75 
High -0.2982 0.64 Q3 -0.0380 1.06 T3 -0.1997 0 
   Q4 -0.2287 -0.17    
   Q5 -0.1653 -0.06    
Education 
Moderate 0.0295 10.07 Q2 0.2056 4.47 T2 -0.0273 2.25 
High -0.2804 -5.37 Q3 -0.0549 46.01 T3 -0.1828 -8.46 
   Q4 -0.2183 -4.71    
   Q5 -0.1355 -18.08    
Smoking history 
Moderate 0.0306 14.18 Q2 0.1999 1.58 T2 -0.0255 -4.49 






   Q4 -0.2227 -2.79    
   Q5 -0.1206 -27.09    
NSAIDs use 
Moderate 0.0259 -3.36 Q2 0.1977 0.46 T2 -0.0285 6.74 
High -0.2970 0.24 Q3 -0.0389 3.46 T3 -0.2011 0.70 
   Q4 -0.2295 0.17    
   Q5 -0.1673 1.15    
Affected 1
st
 degree relative 
Moderate 0.0357 33.21 Q2 0.2099 6.66 T2 -0.0296 10.86 
High -0.2990 0.91 Q3 -0.0405 7.71 T3 -0.2043 2.30 
   Q4 -0.2408 5.11    
   Q5 -0.1641 -0.79    
Screening history 
Moderate 0.0268 0 Q2 0.1632 -17.07 T2 -0.0173 -35.21 
High -0.2530 -14.61 Q3 -0.0579 53.99 T3 -0.1507 -24.54 
   Q4 -0.2095 -8.56    
   Q5 -0.0799 -51.69    
Charlson’s Comorbidity Score 
Moderate 0.0272 1.49 Q2 0.1986 0.91 T2 -0.0280 4.87 
High -0.2956 -0.24 Q3 -0.0383 1.86 T3 -0.1994 -0.15 
   Q4 -0.2311 0.87    
   Q5 -0.1640 -0.85    
1




Table 4.5 Association between dietary scores (numeric) and prostate cancer 
aggressiveness 
 OR 95% CI P(trend) 
MED    
Crude
1
 0.88 (0.82, 0.96) 0.002 
Adjusted
2
 0.92 (0.84, 0.99) 0.03 
DASH    
Crude
1
 0.96 (0.93, 0.99) 0.004 
Adjusted
2
 0.98 (0.95, 1.01) 0.11 
1
 Model includes dietary score, age, total energy intake and race 
2
 Model includes dietary score, age, total energy intake, race, BMI, smoking status, 





Table 4.6 Association between dietary score (numeric) and prostate cancer 
aggressiveness, stratified by race 
 AA EA 
 OR 95% CI P (trend) OR 95% CI P (trend) 
MED       
Crude
1
 0.89 (0.80, 
0.99) 





 0.91 (0.81, 
1.02) 
0.10 0.90 (0.80, 
1.02) 
0.10 
DASH       
Crude
1
 0.96 (0.93, 
1.00) 





 0.99 (0.94, 
1.03) 




 Model includes dietary score, age, and total energy intake  
2
 Model includes dietary score, age, total energy intake, BMI, smoking status, family 



















128/544 1.00 (ref)  1.00 (ref)  
Moderate 
(4-5) 
144/668 0.78 (0.60, 
1.03) 





60/355 0.57 (0.40, 
0.81) 





       
Q1 (11-
18) 
80/344 1.00 (ref)  1.00 (ref)  
Q2 (19-
21) 
93/374 0.97 (0.69, 
1.36) 





50/247 0.76 (0.51, 
1.14) 





61/347 0.63 (0.43, 
0.92) 





48/255 0.67 (0.45, 
1.01) 





       
T1 (<20) 142/590 1.00 (ref)  1.00 (ref)  
T2 (20-
24) 
105/512 0.78 (0.58, 
1.03) 
 0.83 (0.62, 
1.21) 
 
T3 (25+) 85/465 0.65 (0.48, 
0.89) 




 Model includes dietary score, age, total energy intake and race 
2
 Model includes dietary score, age, total energy intake, race, BMI, smoking status, 








Table 4.8 Association between dietary score (categorized) and prostate cancer aggressiveness by race 


















































































































































































































 Model includes dietary score, age, and total energy intake  
2
 Model includes dietary score, age, total energy intake, BMI, smoking status, family history, NSAIDs use, education, screening history, 




Table 4.9: Stratification by potential effect modifiers, MED 
 Numeric Low Moderate High 










 0.88 (0.82, 
0.96) 








<25 56/295 0.95 (0.79, 
1.14) 




25 - <30 126/693 0.83 (0.73, 
0.94) 




30+ 150/579 0.94 (0.83, 
1.06) 










<65 159/900 0.97 (0.87, 
1.08) 




65+ 173/667 0.81 (0.72, 
0.91) 






  0.0098*      0.049* 
Smoking 
status 
         
Never 93/555 0.88 (0.76, 
1.02) 




Former 173/798 0.85 (0.76, 
0.95) 




Current 66/214 0.95 (0.78, 
1.15) 






  0.06*      0.09* 
*p-value <0.10, considered statistically significant interaction 
1
 Base model includes age, race, and total energy intake 
2






Table 4.10: Stratification by potential effect modifiers, DASH quintiles 
 Numeric Q1 Q2 Q3 Q4 Q5 












Main Effect* 0.96 (0.93, 
0.99) 















            
<25 56/295 0.99 (0.93, 
1.06) 








25 - <30 126/693 0.92 (0.87, 
0.96) 








30+ 150/579 0.99 (0.95, 
1.04) 










  0.09*          0.28 
Age**              
<65 159/900 0.99 (0.96, 
1.03) 








65+ 173/667 0.93 (0.89, 
0.97) 










  0.02*          0.36 
Smoking 
status 
             






0.98) 1.19) 1.25) 0.75) 0.92) 
Former 173/798 0.96 (0.92, 
1.00) 








Current 66/214 1.00 (0.93, 
1.08) 










  0.04*          0.20 
*p-value <0.10, considered statistically significant interaction  
1
Base model includes age, race, and total energy intake 
2
Model uses agecat variable in place of age 
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Table 4.11: Stratification by potential effect modifiers, DASH tertiles 
 Numeric T1 T2 T3 






OR 95% CI 
Main Effect
1
 0.96 (0.93, 
0.99) 








<25 56/295 0.99 (0.93, 
1.06) 




25 - <30 126/693 0.92 (0.87, 
0.96) 




30+ 150/579 0.99 (0.95, 
1.04) 










<65 159/900 0.99 (0.96, 
1.03) 




65+ 173/667 0.93 (0.89, 
0.97) 






  0.02*      0.25 
Smoking 
status 
         
Never 93/555 0.93 (0.88, 
0.98) 




Former 173/798 0.96 (0.92, 
1.00) 




Current 66/214 1.00 (0.93, 
1.08) 






  0.04*      0.16 
1
 Base model includes age, race, and total energy intake 
2
 Model uses age category variable in place of age 
*p-value <0.10, considered statistically significant interaction 
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Table 4.12 Association between dietary score (numeric) and prostate cancer 
aggressiveness, including age as categorical variable 
 OR 95% CI P(trend) 
MED    
Crude
1
 0.89 (0.82, 0.96) 0.003 
Adjusted
2
 0.92 (0.85, 1.00) 0.04 
DASH    
Crude
1
 0.96 (0.94, 0.99) 0.01 
Adjusted
2
 0.98 (0.95, 1.01) 0.22 
1
 Model includes dietary score, age (categorical), total energy intake and race 
2
 Model includes dietary score, age (categorical), total energy intake, race, BMI, smoking 





Table 4.13 Association between dietary score (numeric) and prostate cancer 
aggressiveness, stratified by race, including age as categorical variable 
 AA EA 
 OR 95% CI P (trend) OR 95% CI P (trend) 
MED       
Crude
1
 0.89 (0.80, 
0.99) 





 0.91 (0.81, 
1.02) 
0.11 0.92 (0.81, 
1.03) 
0.15 
DASH       
Crude
1
 0.97 (0.93, 
1.01) 





 0.99 (0.94, 
1.03) 




 Model includes dietary score, age (categorical), and total energy intake  
2
 Model includes dietary score, age (categorical), total energy intake, BMI, smoking 





Table 4.14: Association between dietary score (categorized) and prostate cancer 














128/544 1.00 (ref)  1.00 (ref)  
Moderate 
(4-5) 
144/668 0.79 (0.60, 
1.04) 





60/355 0.59 (0.41, 
0.84) 





       
Q1 (11-
18) 
80/344 1.00 (ref)  1.00 (ref)  
Q2 (19-
21) 
93/374 0.98 (0.70, 
1.38) 





50/247 0.81 (0.54, 
1.20) 





61/347 0.67 (0.46, 
0.97) 





48/255 0.71 (0.47, 
1.06) 





       
T1 (<20) 142/590 1.00 (ref)  1.00 (ref)  
T2 (20-
24) 
105/512 0.81 (0.61, 
1.07) 
 0.87 (0.65, 
1.17) 
 
T3 (25+) 85/465 0.69 (0.51, 
0.94) 




 Model includes dietary score, age (categorical), total energy intake and race 
2
 Model includes dietary score, age (categorical), total energy intake, race, BMI, smoking 








Table 4.15 Association between dietary score (categorized) and prostate cancer aggressiveness by race, including age as 
categorical variable 

















































87/338 0.77 (0.52, 
1.15) 
 0.83 (0.55, 
1.26) 
 57/330 0.82 (0.56, 
1.20) 





40/197 0.59 (0.37, 
0.95) 
0.09 0.65 (0.39, 
1.06) 
0.23 20/158 0.63 (0.38, 
1.04) 
0.16 0.69 (0.39, 
1.22) 
0.43 
DASH - quintiles 
Q1  
(11-18) 
44/155 1.00 (ref)  1.00 (ref)  36/172 1.00 (ref)  1.00 (ref)  
Q2  
(19-21) 
53/181 1.06 (0.67, 
1.67) 
 1.26 (0.78, 
2.04) 
 40/193 0.89 (0.53, 
1.47) 





27/111 0.87 (0.51, 
1.50) 
 0.97 (0.55, 
1.70) 
 23/136 0.76 (0.42, 
1.36) 





33/151 0.71 (0.42, 
1.20) 
 0.84 (0.48, 
1.45) 
 28/196 0.61 (0.35, 
1.06) 





25/111 0.75 (0.43, 
1.31) 
0.49 1.06 (0.58, 
1.92) 
0.63 23/144 0.67 (0.37, 
1.21) 
0.41 0.74 (0.39, 
1.41) 
0.63 






T1 80/295 1.00 (ref)  1.00 (ref)  62/295 1.00 (ref)  1.00 (ref)  
T2 54/223 0.82 (0.55, 
1.21) 
 0.90 (0.59, 
1.36) 
 51/289 0.80 (0.53, 
1.21) 
 0.81 (0.52, 
1.24) 
 
T3 48/208 0.73 (0.48, 
1.11) 
0.31 0.87 (0.56, 
1.35) 
0.80 37/257 0.65 (0.41, 
1.02) 




 Model includes dietary score, age (categorical), and total energy intake  
2
 Model includes dietary score, age (categorical), total energy intake, BMI, smoking status, family history, NSAIDs use, education, 




Table 4.16: Spearman correlation between MED and DASH scores 
 DASH 
MED Numeric Tertiles 
Numeric 0.53 ( <.0001)  
Group (Low, Moderate, 
High) 






Table 4.17: Means and standard deviations of selected nutrients and dietary factors across dietary scores 
 Total 
Sample 
MED groups DASH Quintiles DASH Tertiles 












































































































































































































































































































































































5.6 (4.0) 5.6 (3.6) 4.1 
(2.9) 
4.8 (3.6) 5.4 (3.7) 6.2 
(3.8) 
































Abbreviations: Sat. Fat, saturated fat; Carbs, carbohydrates; PUFA, polyunsaturated fatty acids; MUFA, monounsaturated 
fatty acids; Vit. A, vitamin A; Vit. C, vitamin C; Vit. E, vitamin E; Vit. D, vitamin D 
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Table 4.18: Comparison of men excluded for missing data to study population 
included in final analysis  
Characteristic  
Men included in analyses 
(n = 1899) 
 
 
Men excluded due to 




 Mean SD Mean SD  
MED Score 4.2 1.6 4.3 1.6 0.11 
DASH Score 22.0 4.4 22.3 4.2 0.23 
Age 63.1 7.9 63.1 8.2 0.92 
Body Mass Index 29.3 5.2 28.9 5.9 0.31 
MET hours per 
week 
23.9 23.5 20.3 18.0 0.0069 
Total energy 
intake (kcal) 
2482.3 1041.5 3341.7 2456.8 <0.0001 
 n % n %  
Aggressiveness
a
     0.041 
   High 332 17.5 64 23.4  
   Low-
Intermediate 
1567 82.5 210 76.6  
Race     <0.0001 
   AA 908 47.8 222 61.8  
   EA 991 52.2 137 38.2  
Site     <0.0001 
   LA 980 51.6  247 68.8  
   NC 919 48.4 112 31.2  
Education     <0.0001 
   Less than High 
School 
378 19.9 114 32.0  
   High School 
Graduate/Vo-
Tech school 
574 30.2 113 31.7  
   Some 
college/College 
Graduate 
676 35.6 27.53 27.5  




271 14.3 31 8.7  
Smoking Status     <0.0001 
   Never 648 34.1 91 25.5  
   Former 971 51.1 185 51.8  
   Current 280 14.7 81 22.7  
NSAIDs use     0.43 
   No  744 39.2 127 36.9  
   Yes 1155 60.8 217 63.1  
 
79 
Family history in 
first degree 
relative 
    0.92 
   No 1404 73.9 128 73.6  
   Yes 495 26.1 46 26.4  
Screening history     <.0001 
   None 237 12.5 74 20.7  
   DRE only 290 15.3 85 23.7  
   PSA only 77 4.1 15 4.2  




    0.57 
   0 954 50.2 167 47.7  
   1-3 821 43.2 162 46.3  
   4+ 124 6.5 21 6.0  
*
 P-value for differences between included and excluded men determined by t-test for 
numeric variables and chi-square test for categorical variables. 
a 
Prostate cancer aggressiveness is defined as the severity of the cancer at diagnosis based 
on combinations of the Gleason score, morphologic stage, and PSA as follows: high 
aggressive, Gleason sum ≥ 8 OR PSA > 20 ng/mL OR Gleason sum ≥ 7 and stage T3-T4; 
low aggressive, Gleason sum < 7 and stage T1-T2 and PSA < 10 ng/mL; intermediate 
aggressiveness, all other cases. 
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Table 4.19 : Sensitivity analysis for excluded men   
 All men with 
missing outcome 
data excluded 
Any man with 
missing outcome or 
covariate data 
excluded 
All excluded high 
aggressive cases set at 
highest MED/DASH 
category and low-moderate 
cases set at lowest 
MED/DASH category 







0.92 (0.85, 1.00) 
MED Low 1.00 Ref 1.00 Ref 1.00 Ref 




0.86 (0.66, 1.14) 











0.98 (0.95, 1.00) 
DASH Q1 1.00 Ref 1.00 Ref 1.00 Ref 




1.10 (0.79, 1.54) 




0.77 (0.52, 1.13) 




0.73 (0.51, 1.06) 




0.87 (0.58, 1.30) 
DASH T1 1.00 Ref 1.00 Ref 1.00 Ref 




0.84 (0.63, 1.10) 




0.78 (0.57, 1.05) 
All models include dietary score, age, total energy intake, race, BMI, smoking 
status, family history, NSAIDs use, education, screening history, Charlson’s 





Summary of Results 
 Higher conformity to the Mediterranean diet (as measured by the MED score) and 
to the DASH diet (as measured by the DASH score) were associated with decreased odds 
of aggressive prostate cancer. The associations were statistically significant for numeric 
measures of dietary quality in simple models adjusted for age, total energy intake, and 
race. Associations were attenuated when further adjustment for BMI, smoking status, 
family history, NSAIDs use, education, screening history, site, and comorbidities 
occurred, though the inverse direction of the associations remained. Though there is not 
enough evidence to claim healthy dietary patterns improve prostate cancer outcomes, 
high diet quality is unlikely detrimental for prostate health, and the Mediterranean diet, in 
particular, was inversely associated with prostate cancer aggressiveness among the 
highest conformers. There was a significant benefit for both AA men and EA men, 
though the benefit was slightly greater for EA men than AA men. Age modified the 
association between diet quality and prostate cancer aggressiveness: men aged 65 and 
older were shown to have a statistically significantly greater benefit from higher MED 
and DASH scores than men younger than 65 years of age.  
Significance of Findings 
 Previous research that has examined the association between Mediterranean diet 
adherence (measured by the MED or aMED scores) and prostate cancer outcomes have 
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largely found modest, statistically not significant inverse relationships (Ax, Garmo et al. 
2014; Bosire, Stampfer et al. 2013; Kenfield, Du Pre et al. 2014; Möller, Galeone et al. 
2013; Muller, Severi et al. 2009). However, this study found a statistically significant 
inverse relationship between MED score and prostate cancer aggressiveness even after 
adjustment for potential confounders. Men in the highest level of MED score (score=6-9) 
had 34% lower odds of aggressive prostate cancer compared to those with the lowest 
scores (score=0-3). The sample population of this study is unique in that it included AA 
and EA American men in equal proportion; previous research conducted with American 
men sampled men from the NIH-AARP and Health Professionals Follow-up Study 
cohorts represented mostly EA men (Bosire, Stampfer et al. 2013;  Kenfield, Du Pre et al. 
2014). Other research on a priori dietary patterns and prostate cancer outcomes was 
based on Australian and Swedish populations (Muller, Severi et al. 2009; Ax. Garmo et 
la. 2014; Möller, Galeone et al. 2013). The scoring in this study was consistent with the 
Kenfield study (2014) and Möller study (2013); the Kenfield sample had a greater 
number of participants in the ‘high adherence’ category (29.2% vs. 21.9%), though the 
average MED score in the Möller study for both cases and controls was similar to this 
one (4.4/4.4 vs. 4.2/4.0). Bosire, et al. (2013) and Ax, et al. (2014) used the alternative 
MED scoring systems, though the score distributions were similarly distributed in both 
studies were similar to this sample; Muller, et al (2009) compared quartiles, and the 
average aMED score was consistent with averages (4.4 for both cases and controls) seen 
in this study. The case-only sample consisting of half AA men and half EA men, 
combined with the NCI-modified FFQ used to assess diet, may contribute to the deviation 
of this study’s results from previous research. 
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 This is the first known study to evaluate conformity to the DASH diet in relation 
to prostate cancer aggressiveness, though previous work has examined DASH diet 
adherence in relation to other cancers. Anic, et al. (2015) found that greater adherence to 
the DASH diet reduced the risk of lung cancer in former smokers, while another study 
found that higher DASH scores were significantly associated with decreased risk of 
colorectal cancer for men (Jones-McLean, et al. 2015; Dixon, Subar et al. 2007). 
Americans with the highest DASH scores had lower cancer mortality than those with the 
lowest scores in multiple studies (Liese, Krebs-Smith et al. 2015; Harmon, Boushey et al. 
2015; Schwingshackl, Hoffman 2015). The results of this study further corroborate 
previous research that suggests that healthy eating, in accordance with the DASH Eating 
Plan, reduces the risk of several cancers, including aggressive cancer of the prostate. 
 While both the MED and DASH scores are meant to grade healthiness of diet, the 
two have different criteria that define healthiness. All grains are considered beneficial in 
MED scoring, while DASH scoring only considers whole grains as healthy; conversely, 
the MED score classifies all dairy as negative, whereas low-fat dairy contributes 
positively to the DASH score. Fish, but no other animal protein, are positively scored for 
MED; fish are not considered separately for DASH, but only red and processed meats 
contribute (negatively) to the DASH score. The MED also considers moderate alcohol 
and high unsaturated- to-saturated ratio fat intakes beneficial to health; the DASH does 
not account for consumption of either, but does discount high sodium and sugary 
beverage consumption. Vegetable, fruit, nut, and bean consumption in both patterns is 
considered positively. The differences between the two scoring schemes are reflected in 
their moderate correlation (see Table 4.16). 
 
84 
 Neither dietary pattern measure showed significant differences by race. To the 
best of our knowledge, no other studies have examined total dietary quality and prostate 
cancer outcomes stratified by race, so further research is needed to corroborate our 
findings. Higher scores on both dietary pattern measures were modified by age, with a 
significantly greater benefit seen in men aged 65 and older compared to men younger 
than 65 years of age. There is evidence that healthy eating and cancer mortality are not 
associated in older men but midlife diet may affect aging (Nobbs, Yaxley et al. 2015; 
Assmann, Lassale et al. 2015). The results of this study suggest that healthy diets in later 
life may still impact cancer aggressiveness. 
Strengths and Weaknesses 
 This study has several strengths and weaknesses. A main weakness of this study 
was the recruitment process, which did not enroll equal number of research subjects 
based on aggressiveness of disease. Typical case-control studies recruit participants based 
on disease diagnosis, with the intent to maximize power to analyze the disease of interest. 
In the current study, as all participants had prostate cancer, the ability to detect 
differences by cancer aggressiveness was limited by the smaller sample size of high 
aggressive cases. Only 17% of the men included in analysis were diagnosed with high 
aggressive prostate cancer, limiting statistical power. Furthermore, a lack of healthy 
control group and inclusion of only AA and EA men somewhat limits the generalizability 
of this study’s findings. 
 Another potential weakness of this study was the measurement of the dietary data. 
The NCI DHQ, modified to include regional dishes of North Carolina and Louisiana, 
assessed participants’ diet for the year prior to diagnosis. Food frequency questionnaires 
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can be inaccurate, as information is forgotten, misremembered, or purposefully falsified. 
The quality of food frequency questionnaire data is not regarded as highly as alternative 
assessment methods, as complete history is impossible because the questions were 
closed-ended (Willett 2012). Even assuming complete accuracy of dietary information, 
only food intakes for the year prior to diagnosis were assessed. Due to the long latency 
and slow progression periods possible for prostate cancer, diet for the year before 
diagnosis likely has less impact on prostate cancer outcomes than mid-life or lifetime 
diet. 
 Due to missing outcome, exposure, and covariate data, 359 men were excluded 
from analysis. When these men were compared to the final sample, there was a 
significant difference in outcomes between included and excluded men, with excluded 
men (with diagnostic measurements) more likely to have high aggressive prostate cancer. 
When the excluded men with available aggressiveness scores were included in the 
analysis, there was no change in the association estimates; this remained the case when 
previously excluded men with high aggressive prostate cancer were artificially given the 
highest dietary scores and the men with low to intermediate aggressive prostate cancers 
were given the lowest dietary scores. Because the associations were unchanged by 
including previously missing subjects in direct opposition to the hypothesis, it is unlikely 
that selection bias affected the association estimates. 
 Despite these weaknesses, this study also had a number of strengths. Because 
recruitment was based on race rather than disease status, the sample population was ideal 
to study racial differences in prostate cancer aggressiveness. While no significant racial 
differences were found in this study, the study’s design lends confidence to the 
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conclusion that the effect of overall diet quality on prostate cancer aggressiveness is 
similar for AA and EA men. The recruitment design also limited the recall bias 
commonly associated with case-control studies and dietary recalls. All participants had 
diagnosed prostate cancer, and it is unlikely that high aggressive cases remembered their 
eating habits differently than men with low or intermediate aggressive disease.  Also, due 
to the high prevalence of indolent prostate cancer in the American population, enrolling 
only men with confirmed prostate cancer and utilizing low-intermediate aggressive cases 
as the comparison group may have reduced outcome misclassification. In traditional case-
control studies, some “controls” may be erroneously assumed to be disease-free because 
they had not been screened previously. Another strength of PCaP is that data on a large 
number of potential confounders and effect modifiers were collected from research 
subjects and used in the analyses. However, residual or unmeasured confounding cannot 
be ruled out in any observational study. Results in the fully adjusted models were 
attenuated from those in the simple models, suggesting some confounding by the 
included covariates.   
Recommendations for Future Research 
 Higher conformity to Mediterranean and DASH diets was associated with lower 
odds of aggressive prostate cancer. Further analyses using this dataset should examine 
each component of the MED and DASH diets and their associations with prostate cancer 
aggressiveness. The Mediterranean diet differentiates fish consumption from other 
protein sources, unlike the DASH Easting Plan, which does not. Since fish has been 
shown to decrease prostate cancer risk in several previous studies, determining if high 
scores in the fish component of the MED score are associated with prostate cancer 
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aggressiveness would further clarify the possible benefits of consuming fish and omega-3 
fatty acids. Similar analyses using each pattern’s components could better define the 
potential benefits and harms of specific food groups.  
 The modification of the association between dietary pattern and aggressiveness by 
age should be further explored. Diet was measured only in the year prior to diagnosis for 
all men, regardless of age, so we were unable to examine diet at other life stages or 
changes in diet over time. Possible effects of improving diet at various stages of life 
would help explain the timeline for dietary modifications on health and shape dietary 
recommendations for each age group.  
 In conclusion, it was found that men who consume diets with higher conformity 
to the Mediterranean diet and the DASH Eating Plan were less likely to be diagnosed 
with high aggressive prostate cancer than those who scored lower; this association was 
modified by age, with men aged 65 and older receiving greater benefit from a healthy diet 
in relation to prostate cancer stage than men younger than 65. This study contributes to 
the body of literature on overall diet and prostate cancer, particularly as it relates to 
aggressiveness of disease. While previous studies have been inconclusive on the 
association between a priori dietary patterns and prostate cancer risk, the results of this 
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